Neuro2Go offers a convenient way to talk to a board-certified neurologist, which will now provide the Sampled Alzheimer’s Risk Test, to assess the genetic risk of cognitive decline due to Alzheimer’s disease. The test uses Cytox’s genoSCORE technology to generate a comprehensive genetic analysis for the risk of Alzheimer’s disease from a simple saliva sample.
Neuro2Go is a division of First Choice Neurology (FCN), one of the largest neurology practices in the US, which specializes in access to virtual, interactive video sessions with neurologists. This latest collaboration with Neuro2Go extends the use of the Alzheimer’s Risk Test beyond in-clinic practice and into telehealth.
During a virtual visit, Neuro2Go neurologists will assess those interested in understanding their risk of Alzheimer’s dementia and advise whether they are suitable for the test. Individuals wishing to proceed will receive a saliva collection device with pre-paid packaging so they can send their sample to the lab for analysis. Once the results are available, Neuro2Go will arrange a further virtual visit to discuss the results and provide appropriate recommendations and medical guidance.
Dr. Richard Pither, CEO of Cytox, commented: “At Cytox our mission is to transform how people are managed within the Alzheimer’s disease care pathway. Neuro2Go is an excellent partner for our genoSCORE-powered Alzheimer’s Risk Test, provided by Sampled, that can provide access to the test throughout the US. We’re all looking forward to working with the Neuro2Go team in bringing this test to those interested in understanding their genetic risk of Alzheimer’s disease.
Dr. Jeff Gelblum, a Senior Neurologist at Neuro2Go, explained, “Neuro2Go is the virtual arm of First Choice Neurology, one of the leading neurology groups in the US. To support our patient community, we are constantly seeking to bring new medical technologies into our practices and out to our patients. Alzheimer’s disease affects over 46 million people in the world1. We see this new test as a powerful tool to guide patients towards effective lifestyle and therapeutic interventions that can have a significant impact on delaying the onset of disease symptoms and cognitive decline.”
Schedule a Virtual Visit to Discuss the Sampled Alzheimer’s Risk Test
If you are interested in taking the Sampled Alzheimer’s Risk Test, schedule a virtual visit with one of our board-certified neurologists.
About Cytox (www.cytoxgroup.com)
Without new drug therapies, the economic and healthcare cost burden of dementia – including Alzheimer’s disease (AD) – is estimated to exceed $1tn per year in the next decade2. AD – a highly complex disease with risk factors based on genetics, lifestyle, age, and environment. Cytox’s products genoSCORETM and genoTORTM use Polygenic Risk Scoring (PRS) to predict the risk of individuals developing AD and to improve clinical trial outcomes through patient stratification and the genetic characterization of the disease.
About genoSCORE™
The genoSCORE technology underpins non-invasive, genetic tests to assess the risk of cognitive decline due to Alzheimer’s disease (AD). The test, which uses a simple blood or saliva sample, analyses over 100,000 single nucleotide polymorphisms (SNPs) – small genetic variations – that are associated with AD. As such, the test generates a patient-specific polygenic risk score (PRS).
Clinicians can use the test to assess patients for the risk of developing Alzheimer’s, before symptoms arise, prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore, the test’s simplicity of use would enable elderly and vulnerable patients to self-isolating due to COVID-19, or not wishing or being easily able to attend healthcare settings, to provide a suitable sample from home.
Developers of new AD drug therapies can also test to identify and recruit patients to clinical studies, ensuring the selection of the most suitable candidates, those most likely to experience cognitive decline over the time period of the study.
References:
1. World Alzheimer’s Report 2015 www.alz.co.uk/research/WorldAlzheimerReport2015.pdf
2. Lancet Commission: Dementia prevention, intervention, and care: 2020 https://pubmed.ncbi.nlm.nih.gov/32738937/